Julie Laterreur

Julie completed her B.S. degree in Chemistry from University of Sherbrooke and her M.S. degree in Biochemistry from Concordia University. She then spent the next 16 years at Vertex Pharmaceutical working as DMPK lead on numerous projects including modulator of CFTR, IBD, kidney diseases, and HCV. She has been involved in more than 10 regulatory submissions (CTA, IND, NDA) including NDA submission for FDA approved drug, Trikafta.